---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-090855"
form_type: "8-K/A"
ticker: null
cik: "0001780097"
company_name: "Baudax Bio, Inc."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:32:40.901869+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Baudax Bio transfers ANJESO assets to Alkermes, terminates related agreements, amends credit facility

## Summary
- Transferred patents, trademarks, equipment, data, and ANJESO NDA to Alkermes; no further payments due under terminated ANJESO agreements.
- Amended credit agreement: lenders consented to asset sale, released liens on transferred assets, reduced minimum liquidity covenant to $2.5M.
- Issued warrants to MAM Eagle Lender for 785,026 shares at $1.8951/share, exercisable for 10 years; registration rights granted.
- Company will withdraw ANJESO NDA and transfer to Alkermes if requested; acquired regulatory approvals included in transfer.

## SEC filing metadata
- accession: 0001193125-23-090855
- form_type: 8-K/A
- cik: 0001780097
- company_name: Baudax Bio, Inc.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/d460062d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-090855
- JSON: https://secwatch.observer/filing/0001193125-23-090855.json
- Plain text: https://secwatch.observer/filing/0001193125-23-090855.txt

## Key facts
- Debt Financings
  Baudax Bio, Inc. amended credit facility with Wilmington Trust, National Association.
  - Instrument: credit facility
  - Counterparty: Wilmington Trust, National Association
  - Event: amendment
  source text: LLC, Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party and (ii) the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (the “Transfer Agreement”), each as described in greater detail in the Original 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm
- M&A Transactions
  Baudax Bio, Inc. completed a disposition involving Alkermes Pharma Ireland Limited (closed 2023-03-29).
  - Action: disposition
  - Counterparty: Alkermes Pharma Ireland Limited
  - Closing: 2023-03-29
  source text: LLC, Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party and (ii) the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (the “Transfer Agreement”), each as described in greater detail in the Original 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm
- Material Agreements
  Baudax Bio, Inc. amended Amendment No. 5 and Consent to Credit Agreement with Wilmington Trust, National Association, as agent, and the lenders party thereto (effective 2023-03-29).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Wilmington Trust, National Association, as agent, and the lenders party thereto
  - Effective: 2023-03-29
  source text: On March 29, 2023 (the “Closing Date”), Baudax Bio, Inc. (the “Company”) entered into that certain Amendment No. 5 and Consent to Credit Agreement (the “Amendment”) by and among the Company, Baudax Bio N.A. LLC (“Baudax LLC”), Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent (the “Agent”) and the lenders party thereto (the “Lenders”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm
- Material Agreements
  Baudax Bio, Inc. terminated ANJESO Agreements (PSA, ATLA, Manufacturing Agreement) with Alkermes Pharma Ireland Limited (effective 2023-03-29).
  - Action: termination
  - Agreement: supply
  - Counterparty: Alkermes Pharma Ireland Limited
  - Effective: 2023-03-29
  source text: Alkermes Agreement On March 29, 2023, the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (“Alkermes”) (the “Transfer Agreement”). Under the terms of the Transfer Agreement, the Company transferred the rights to certain patents, trademarks, equipment, data and other rights related to ANJESO ® (the “Assets”) to Alkermes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm
- Material Agreements
  Baudax Bio, Inc. entered into Asset Transfer Agreement with Alkermes Pharma Ireland Limited (effective 2023-03-29).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Alkermes Pharma Ireland Limited
  - Effective: 2023-03-29
  source text: On March 29, 2023, the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (“Alkermes”) (the “Transfer Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm
- Material Agreements
  Baudax Bio, Inc. entered into Registration Rights Agreement with MAM Eagle Lender, LLC (effective 2023-03-29).
  - Action: entry
  - Counterparty: MAM Eagle Lender, LLC
  - Effective: 2023-03-29
  source text: the registration rights agreement by and between the Company and MAM Eagle Lender, LLC, entered into on March 29, 2023 (the “Registration Rights Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.